Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OBIO
SELLOrchestra BioMed Holdings, Inc. · Healthcare · United States · $224M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Orchestra BioMed Holdings, Inc. is a medical device company focused on developing disruptive therapies for heart failure and hypertension, with its lead product, BackBeat Cardiac Neuromodulation Therapy (CNT), targeting improved outcomes for HFpEF patients. Its competitive moat lies in its proprietary, patented technology addressing significant unmet medical needs in large patient populations, potentially establishing a new standard of care. Orchestra BioMed is a clinical-stage company leveraging strategic partnerships with major medical device firms to validate and commercialize its innovative solutions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5M | 2.8M | 2.6M | 33.5M | 111.6% | 32.7M | 0.5M | 0.7M | -86.0% |
| EPS | -1.06 | -1.48 | -1.66 | -1.11 | — | -0.97 | -1.50 | -1.46 | — |
| Shares | 31.6M | 35.8M | 38.2M | 57.0M | +80.4% | 59.9M | — | — | — |
| Debt | 11.9M | 1.7M | 16.5M | 16.0M | 10.4% | 15.8M | — | — | — |
| Equity | 52.5M | 68.0M | 33.0M | 53.6M | 0.7% | — | — | — | — |
| Op CF | -29.3M | -46.1M | -50.6M | -49.0M | — | -54.5M | — | — | — |
| Inv CF | -64.1M | 10.7M | 13.1M | -26.9M | — | — | — | — | — |
| Fin CF | 103.3M | 46.2M | 29.2M | 88.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc.(you) | $224M | 21 | SELL |
| CHRS | Coherus Oncology, Inc. | $217M | 20 | STRONG SELL |
| MGNX | MacroGenics, Inc. | $235M | 25 | SELL |
| IMRX | Immuneering Corporation | $279M | 21 | SELL |
| KROS | Keros Therapeutics, Inc. | $199M | 18 | STRONG SELL |
| SRZN | Surrozen, Inc. | $229M | 15 | STRONG SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 23 | SELL |
| RNA | Atrium Therapeutics, Inc. | $197M | 16 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 14 | STRONG SELL |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 24 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%